References
- Panay N, Ylikorkala O, Archer D F, et al. Ultra-low-dose estradiol and norethisterone acetate: effective menopause symptom relief. Climacteric 2007; 10: 120–131
- Wingrove C S, Garr E, Godsland I F, Stevenson J C. 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998; 1406: 169–174
- White W, Pitt B, Preston R, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005; 112: 1979–1984
- Coelingh Bennink H, Holinka C, Diczfalusy E. Estetrol review: profile and potential clinical applications. Climacteric 2008; 11(Suppl 1)47–58
- Stovall D, Pinkerton J. MF-101, an estrogen receptor β agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women. Curr Opin Invest Drugs 2009; 10: 365–371
- Kung A, Chu E, Xu L. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis. Expert Opin Pharmacother 2009; May 15, [Epub ahead of print]
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103–111